Table 1.
Characteristics of the studies and patients included in the review.
| Studies | Countries | Study design | Number of cases | Age | Type of treatment |
|---|---|---|---|---|---|
| Koskas [39] | Paris, France | CR∗ | Case 1 Case 2 Case 3 |
41 32 35 |
NES (20 mg/d) MA (160 mg/d) NG (5 mg/d) |
|
| |||||
| Brown [40] | Houston, USA | CR∗ | Case 1 | 18 | LNG-IUDs (20 μg/d) |
|
| |||||
| Park [45] | Seoul, Korea | MRCS | 14 | (23-40) | MA (40-240 mg/d)/MPA (80-1000 mg/d) |
|
| |||||
| Rossetti [41] | Bergamo, Italy | CR∗ | Case 1 Case 2 |
(27–31) | MA (160 mg/d) |
|
| |||||
| Kim [42] | Daegu, Korea | CR∗ | Case 1 | 13 | 1°. MA (160 mg/d) 2°. MPA (10 mg/d) |
|
| |||||
| Hwang [34] | Seoul, Korea | ROS | Case 1 Case 2 Case 3 Case 4 Case 5 |
28 25 29 31 39 |
MPA (500 mg/d) + LNG-IUDs (20 μg/d) |
|
| |||||
| Pal [43] | Houston, Texas | RCS | 8 | (18-85) | LNG-IUDs (20 μg/d) |
|
| |||||
| Chae [35] | Seoul, Korea | ROS | 11 | (28-45) | MPA (500 mg/d) + LNG-IUDs |
|
| |||||
| Roberti Maggiore [36] | Milan, Italy | ROS | 4 | (31-37) | LNG-IUDs |
|
| |||||
| Yu [37] | Beijing, China | ROS | 8 | (22-35) | 3 MPA (500 mg/d) 3 MA (160 mg/d) 1 GnRHa (3,75 mg every 4 weeks) + AI + LNG-IUDs 1 MA(160 mg/d) → GnRHa (3,75 mg every 4 weeks) + LNG-IUDs |
|
| |||||
| Falcone [44] | Naples, Italy | PS | 23 | (28-44) | 12: HR + LNG-IUDs 4: HR + MA (160 mg/day) 4: LNG-IUDs 1: NES (10 mg/day) 1: LNG-IUDs + MA (160 mg/day) 1: MA (160 mg/day) |
|
| |||||
| Shan [38] | Shanghai, China | ROS | Case 1 Case 2 Case 3 Case 4 |
28 38 35 36 |
MA (160 mg/day) + MET MA (160 mg/day) MA (160 mg/day), MA + MET, LNG-IUDs + GnRHa + MET, LNG-IUDs + GnRHa + LE + MET MA (160 mg/day) + MET |
|
| |||||
| Total | 84 | 13-85) | |||
AI: aromatase inhibitor; CR∗: case report; CR: complete response; GnRHa: gonadotropin-releasing hormone agonist; MA: megestrol acetate; MPA: medroxyprogesterone acetate; MRCS: multicenter retrospective cohort study; NES: norethisterone; NG: normegestrol; LE: letrozole; LNG-IUDs: levonorgestrel-releasing intrauterine devices; PS: prospective study; RCS: retrospective case series; ROS: retrospective observational study; SD: stable disease.